This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barrabés, J. A. Articles by Soler-Soler, J. Search for Related Content PubMed PubMed Citation Articles by Barrabés, J. A. Articles by Soler-Soler, J.

Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs

José A. Barrabés, MD^*, David Garcia-Dorado, MD, FACC^*,*, Maribel Mirabet, PhD^*, Rosa-Maria Lidón, MD^*, Bernat Soriano, PharmD, Marisol Ruiz-Meana, PhD^*, Pilar Pizcueta, PhD, José Blanco, MD^*, Yolanda Puigfel, RN^* and Jordi Soler-Soler, MD, FACC^*

^* Servicios de Cardiología, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Medicina Nuclear, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Institut de Malalties Digestives, Hospital Clínic, Barcelona, Spain

View larger version (40K): [in a new window]   Figure 1 Bleeding time (top) and ex vivo aggregation induced by 10 µmol/l of adenosine diphosphate (ADP) (bottom) at several time points of the experiment. P values refer to the effect of treatment on bleeding time and aggregation according to general linear model analysis of variance for repeated measures.

View larger version (16K): [in a new window]   Figure 2 Activity of myeloperoxidase (MPO) in control and reperfused myocardium.

View larger version (15K): [in a new window]   Figure 3 Correlation between specific technetium-99m (99mTc) activity (top) and myeloperoxidase (MPO) activity (bottom) in reperfused myocardium, reflecting platelet and polymorphonuclear leukocytes accumulation, respectively, and infarct size.

View larger version (17K): [in a new window]   Figure 4 Area at risk, expressed as a percentage of ventricular mass (left axis) and infarct size, expressed as a percentage of the area at risk (right axis).